AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bhbusiness

Published November 5, 2026 · Updated November 6, 2026

LifeStance CEO Teases Psychedelics in the Company's Future

Read the full story at Bhbusiness

(Nasdaq: LFST) said it's too early to talk about how it will handle the looming approval of the first genuinely psychedelic intervention. However,.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics